Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer.

Affiliation

Department of Clinical Oncology, The Chinese University of Hong Kong, LG, LKS Specialist Clinic (North Wing), Prince of Wales Hospital, Sha Tin, N.T., Hong Kong, China. Electronic address: [Email]

Abstract

With the availability of several epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs), sequential therapy could potentially render EGFR mutation-positive non-small cell lung cancer a chronic disease in some patients. In this retrospective analysis of EGFR mutation-positive (Del19/L858R) patients receiving first-line afatinib in LUX-Lung 3, 6, and 7, we assessed uptake of, and outcomes following, subsequent therapies including the third-generation EGFR TKI, osimertinib.

Keywords

Afatinib,Non-small cell lung cancer,Osimertinib,

OUR Recent Articles